LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.45 -0.23

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.45

Max

21.45

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -21M
Pardavimai	14M 54M
Pelno marža	-39.611
Darbuotojai	178
EBITDA	-3.8M -23M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	-3.62% downside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1B 2.2B
Ankstesnė atidarymo kaina	21.68
Ankstesnė uždarymo kaina	21.45

Naujienos nuotaikos

By Acuity

50%

192 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-08 23:55; UTC

Uždarbis

Review & Preview: Still Going Strong -- Barrons.com

2026-05-08 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 20:49; UTC

Uždarbis

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

2026-05-08 20:25; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

2026-05-08 19:43; UTC

Uždarbis

Cencosud 1Q Net $115M

2026-05-08 19:20; UTC

Rinkos pokalbiai

Oil Futures End Session Higher, But Down on the Week -- Market Talk

2026-05-08 19:18; UTC

Uždarbis

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

2026-05-08 19:16; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:08; UTC

Uždarbis

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

2026-05-08 19:05; UTC

Uždarbis

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

2026-05-08 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

2026-05-08 18:51; UTC

Uždarbis

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

2026-05-08 18:49; UTC

Uždarbis

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

2026-05-08 18:41; UTC

Uždarbis

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

2026-05-08 17:38; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

2026-05-08 17:14; UTC

Uždarbis

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

2026-05-08 17:04; UTC

Rinkos pokalbiai

Zcash Caps Off Parabolic Week -- Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-05-08 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-08 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-08 15:39; UTC

Rinkos pokalbiai

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

2026-05-08 15:39; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-08 15:39; UTC

Rinkos pokalbiai

Canada's Job Market Sees Worst Start in Years -- Market Talk

2026-05-08 15:36; UTC

Rinkos pokalbiai

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

2026-05-08 15:20; UTC

Rinkos pokalbiai

'Altcoin Season' Indicator on the Rise -- Market Talk

2026-05-08 15:20; UTC

Rinkos pokalbiai

Uždarbis

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

2026-05-08 15:05; UTC

Rinkos pokalbiai

Bitcoin Slips Back Below the $80k Mark -- Market Talk

2026-05-08 14:42; UTC

Rinkos pokalbiai

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

2026-05-08 14:39; UTC

Rinkos pokalbiai

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

-3.62% į apačią

12 mėnesių prognozė

Vidutinis 20.75 USD -3.62%

Aukščiausias 21.5 USD

Žemiausias 17 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

192 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.